Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

Maria A. Velez, Edward B. Garon

Clin Cancer Res (2023) 29 (4): 691–693.

https://doi.org/10.1158/1078-0432.CCR-22-3229

Published: 16 February 2023

View article titled, Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

Journal Articles

Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS⁺ CD4⁺ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

Philippe Rochigneux, Aaron Lisberg, Alejandro Garcia, Samuel Granjeaud, Anne Madroszyk, Stéphane Fattori, Anthony Gonçalves, Raynier Devillier, Pauline Maby, Nassim Salem, Laurent Gorvel, Brice Chanez, Jaklin Gukasyan, James Carroll, Jonathan Goldman, Anne Sophie Chretien, Daniel Olive, Edward B. Garon

Clin Cancer Res (2022) 28 (23): 5136–5148.

https://doi.org/10.1158/1078-0432.CCR-22-1386

Published: 01 December 2022

View article titled, Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

Includes: Supplementary data

Journal Articles

cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

Shuo Li, Weihua Zeng, Xiaohui Ni, Yonggang Zhou, Mary L. Stackpole, Zorawar S. Noor, Zuyang Yuan, Adam Neal, Sanaz Memarzadeh, Edward B. Garon, Steven M. Dubinett, Wenyuan Li, Xianghong Jasmine Zhou

Clin Cancer Res (2022) 28 (9): 1841–1853.

https://doi.org/10.1158/1078-0432.CCR-21-1242

Published: 02 May 2022

View article titled, cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

Includes: Supplementary data

Journal Articles

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin-Yuan Shih, Luis Paz-Ares, Bente Frimodt-Moller, Annamaria H. Zimmermann, Sameera Wijayawardana, Carla Visseren-Grul, Martin Reck, for the RELAY study investigators

Clin Cancer Res (2021) 27 (19): 5258–5271.

https://doi.org/10.1158/1078-0432.CCR-21-0273

Published: 01 October 2021

View article titled, RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Edward B. Garon, Alexander I. Spira, Melissa Johnson, Lyudmila Bazhenova, Joseph Leach, Amy L. Cummings, Albert Candia, Robert L. Coffman, Mary J. Janatpour, Robert Janssen, Erick Gamelin, Laura Q.M. Chow

Clin Cancer Res (2021) 27 (16): 4566–4573.

https://doi.org/10.1158/1078-0432.CCR-21-0263

Published: 15 August 2021

View article titled, A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Edward B. Garon

Clin Cancer Res (2021) 27 (4): 905–907.

https://doi.org/10.1158/1078-0432.CCR-20-4026

Published: 15 February 2021

View article titled, Osimertinib plus Ramucirumab: The Best of Both Worlds?

Journal Articles

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M. Zaretsky, Tristan R. Grogan, Hira Rizvi, Daniel K. Wells, James Carroll, Amy Cummings, John Madrigal, Benjamin Jones, Jacklin Gukasyan, I. Peter Shintaku, Dennis Slamon, Steven Dubinett, Jonathan W. Goldman, David Elashoff, Matthew D. Hellmann, Antoni Ribas, Edward B. Garon

Clin Cancer Res (2019) 25 (16): 5061–5068.

https://doi.org/10.1158/1078-0432.CCR-18-4275

Published: 15 August 2019

View article titled, Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna G. Kondic, Keaven M. Anderson, Andrew G. Robinson, Edward B. Garon, Jonathan Wesley Riess, Lokesh Jain, Kapil Mayawala, Jiannan Kang, Scot W. Ebbinghaus, Vikram Sinha, Dinesh P. de Alwis, Julie A. Stone

Clin Cancer Res (2018) 24 (23): 5841–5849.

https://doi.org/10.1158/1078-0432.CCR-18-0415

Published: 03 December 2018

View article titled, Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Includes: Supplementary data

Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Clin Cancer Res (2018) 24 (5): 1038–1047.

https://doi.org/10.1158/1078-0432.CCR-17-2289

Published: 28 February 2018

View article titled, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Includes: Supplementary data

Journal Articles

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

Edward B. Garon, Ani Balmanoukian, Omid Hamid, Rina Hui, Leena Gandhi, Natasha Leighl, Matthew Gubens, Jonathan W. Goldman, Gregory M. Lubiniecki, Kenneth Emancipator, Marisa Dolled-Filhart, Jared Lunceford, Kevin Gergich, Naiyer A. Rizvi

Clin Cancer Res (2014) 20 (2_Supplement): A20.

https://doi.org/10.1158/1078-0432.14AACRIASLC-A20

Published: 16 January 2014

View article titled, Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

Journal Articles

Abstract IA18: Early but promising data: PD-1 inhibitors in non-small cell lung cancer.

Edward B. Garon, Brian R. Wolf, Deborah JL Wong, Jonathan W. Goldman

Clin Cancer Res (2014) 20 (2_Supplement): IA18.

https://doi.org/10.1158/1078-0432.14AACRIASLC-IA18

Published: 16 January 2014

View article titled, Abstract IA18: Early but promising data: PD-1 inhibitors in non-small cell lung cancer.

Journal Articles

Characteristics of Lung Cancers Harboring NRAS Mutations

Clin Cancer Res (2013) 19 (9): 2584–2591.

https://doi.org/10.1158/1078-0432.CCR-12-3173

Published: 30 April 2013

View article titled, Characteristics of Lung Cancers Harboring NRAS Mutations

Includes: Supplementary data

Journal Articles

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Clin Cancer Res (2012) 18 (11): 3163–3169.

https://doi.org/10.1158/1078-0432.CCR-11-3090

Published: 31 May 2012

View article titled, Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Journal Articles

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Pasi A. Jänne, David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon, Feng Guo, Steven Wong, Jane Liang, Stephen Letrent, Robert Millham, Ian Taylor, S. Gail Eckhardt, Jan H.M. Schellens

Clin Cancer Res (2011) 17 (5): 1131–1139.

https://doi.org/10.1158/1078-0432.CCR-10-1220

Published: 01 March 2011

View article titled, Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Includes: Supplementary data

NARROW

Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS⁺ CD4⁺ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.

Abstract IA18: Early but promising data: PD-1 inhibitors in non-small cell lung cancer.

Characteristics of Lung Cancers Harboring NRAS Mutations

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only